Literature DB >> 15206499

Meeting the needs of patients with COPD: patients' preference for the Diskus inhaler compared with the Handihaler.

A C Moore1, S Stone.   

Abstract

This study assessed preference and ease of use of the Diskus and the Handihaler in symptomatic chronic obstructive pulmonary disease (COPD) patients. No patient had used either device before. Patients were given a questionnaire to assess the inhalers and to rank the most important feature of an inhaler. Patients in Germany (n = 125) and The Netherlands (n = 131) with a mean age of 60 participated. Fifty-eight percent of German patients and 69% of Dutch patients had no problems using the Diskus compared to only 11 and 32%, respectively, using the Handihaler (p < 0.001). Overall, 79% of patients would be happy to use the Diskus and 46% the Handihaler if their physician suggested it. However, 35% of Dutch patients and 72% of German patients stated they would not be happy to use the Handihaler. The Diskus was rated higher than the Handihaler for the top three features of an ideal inhaler. Overall the Diskus inhaler was preferred by 67% of patients.

Entities:  

Mesh:

Year:  2004        PMID: 15206499     DOI: 10.1111/j.1368-5031.2004.00123.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  9 in total

1.  Management of chronic obstructive pulmonary disease associated with chronic bronchitis with inhaled fluticasone propionate/salmeterol (ADVAIR DISKUS) 250/50: results of a patient experience trial.

Authors:  Stuart Stoloff; Steven Samuels; Donna Kerney; Christy P Brown
Journal:  MedGenMed       Date:  2006-03-29

2.  Comparing usability of NEXThaler(®) with other inhaled corticosteroid/long-acting β2-agonist fixed combination dry powder inhalers in asthma patients.

Authors:  Thomas Voshaar; Monica Spinola; Patrick Linnane; Alice Campanini; Daniel Lock; Anthony Lafratta; Mario Scuri; Barbara Ronca; Andrea S Melani
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2013-12-03       Impact factor: 2.849

3.  The Delivery of High-Dose Dry Powder Antibiotics by a Low-Cost Generic Inhaler.

Authors:  Thaigarajan Parumasivam; Sharon S Y Leung; Patricia Tang; Citterio Mauro; Warwick Britton; Hak-Kim Chan
Journal:  AAPS J       Date:  2016-09-27       Impact factor: 4.009

Review 4.  COPD: maximization of bronchodilation.

Authors:  Stefano Nardini; Gianna Camiciottoli; Salvatore Locicero; Rosario Maselli; Franco Pasqua; Giovanni Passalacqua; Riccardo Pela; Alberto Pesci; Alfredo Sebastiani; Alessandro Vatrella
Journal:  Multidiscip Respir Med       Date:  2014-10-15

5.  Patient preferences for dry powder inhaler attributes in asthma and chronic obstructive pulmonary disease in France: a discrete choice experiment.

Authors:  Natalia Hawken; Saku Torvinen; Mohamed-Elmoctar Neine; Ikbel Amri; Mondher Toumi; Samuel Aballéa; Adam Plich; Nicolas Roche
Journal:  BMC Pulm Med       Date:  2017-07-06       Impact factor: 3.317

Review 6.  Medication adherence issues in patients treated for COPD.

Authors:  Ruben D Restrepo; Melissa T Alvarez; Leonard D Wittnebel; Helen Sorenson; Richard Wettstein; David L Vines; Jennifer Sikkema-Ortiz; Donna D Gardner; Robert L Wilkins
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

Review 7.  The Diskus: a review of its position among dry powder inhaler devices.

Authors:  H Chrystyn
Journal:  Int J Clin Pract       Date:  2007-06       Impact factor: 2.503

8.  Evaluation of patient preference and willingness to pay for attributes of maintenance medication for chronic obstructive pulmonary disease (COPD).

Authors:  Ariane K Kawata; Leah Kleinman; Gale Harding; Sulabha Ramachandran
Journal:  Patient       Date:  2014       Impact factor: 3.883

Review 9.  Patients' perspectives and preferences in the choice of inhalers: the case for Respimat(®) or HandiHaler(®).

Authors:  Pieter Nicolaas Richard Dekhuijzen; Federico Lavorini; Omar S Usmani
Journal:  Patient Prefer Adherence       Date:  2016-08-18       Impact factor: 2.711

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.